Fig 1.
Representative images of immunostainings.
(A, B) Immunoreactivity for chromogranin A, (C, D) Ki67 and (E, F) p53. The left panel demonstrates staining of a pancreatic primary tumor. The right panel shows the respective staining from a rectal primary tumor. Scale bar = 100 μm.
Table 1.
Tumour characteristics.
Fig 2.
Immunohistochemical images of scattered and dense staining pattern.
Scattered and dense staining pattern for two p53 immunoreactive tumors. (A) Scattered type. Single immunoreactive cells spread out in the whole tumor sample. (B) Dense type. Widespread immunoreactivity of the entire tumor specimen. (C) and (D) represent Ki67 for each tumor respectively. Scale bar = 100 μm.
Table 2.
p53 protein expression in relation to clinicopathological variables.
Fig 3.
Kaplan-Meier survival curves for GEP-NECs divided according to primary tumor origin and p53 immunoreactivity. (A) Progression-free survival (PFS) for the complete cohort of 124 patients, p = 0.97. (B) Overall survival (OS) for the complete cohort of 124 patients, p = 0.54. (C) PFS for colorectal patients p = 0.03 (D) and (E) PFS and OS for colorectal patients with distant metastases, p = 0.01 and p = 0.02 respectively.
Table 3.
Median PFS and OS in p53 immunoreactive and non-immunoreactive groups.
Table 4.
Univariate analysis of prognostic parameters.
Table 5.
Multivariate analysis of prognostic parameters.